HomeTagsFDA

FDA

Capricor Therapeutics Announces BMD Orphan Drug Designation and DMD Program Regulatory Development for Deramiocel (CAP-1002)

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

Solid Biosciences Plans to Request a Meeting with the FDA in mid-2025 to Discuss Potential Accelerated Approval Pathways for SGT-003

GenAssist Announces FDA Approval of New Drug Application for GEN6050X Exon 50 Skipping Therapy

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

FDA Grants Rare Pediatric Disease Designation to Nippon Shinyaku’s Exon 51 Skipping Study (NS-051/NCNP-04)

3 Drugs Receiving Accelerated Approval from the FDA and Reviewed by the Office of Inspector General Raised Concerns

The FDA Designates IPS HEART’s GIVI-MPC Stem Cell Therapy for Becker Muscular Dystrophy an Orphan Drug

What is Ataluren (Translarna)? What is Ataluren Used For?

1 234 Page 3 of 4

Popular

Frequently Asked Questions About Elevidys Used for DMD

Can Ekinci - August 21, 2026

Must Read

IPS HEART Aims to Restore Full-Length Dystrophin with Two Regenerative Cell Therapies for Duchenne Muscular Dystrophy

20 Important Things You Need to Know About DMD Genetic Testing

Mutations Amenable to Exon 50 Skipping Therapies in Duchenne Muscular Dystrophy

About us

Together, we will keep fighting for better treatments and access for everyone with Duchenne.

Powered by Hostinger

Latest Articles

Entrada Therapeutics ENTR-601-45: Early Exon 45 Skipping Study Shows Increased Dystrophin Production

Press Releases October 14, 2026 0

Entrada Therapeutics has announced positive initial results from its...

Entrada Therapeutics Advances ENTR-601-44 to 18 mg/kg in Its Duchenne Exon 44 Skipping Study

Press Releases October 14, 2026 0

Entrada Therapeutics has received clearance to test the highest...

Sapreme Therapeutics Reports Strong Preclinical Dystrophin Restoration With SPM-2551 in Duchenne

Research October 14, 2026 0

Sapreme Therapeutics has announced promising preclinical results for SPM-2551,...

Most Popular

Frequently Asked Questions About Elevidys Used for DMD

Approved Therapies August 21, 2026 0

Duchenne muscular dystrophy (DMD) is a genetic condition that...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Editorials April 10, 2026 0

The landscape of potential new gene therapies for Duchenne...

The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control

Editorials April 6, 2026 0

The duchenne muscular dystrophy treatment cost has become one...

© 2024 - 2026 DMD Warrior. All rights reserved.